Higher frequency of subclonal anti-EGFR resistance mutations in post-treatment samples from patients with colorectal cancer liver metastases following anti-EGFR-based conversion chemotherapy.
BACKGROUND/AIMS: Initially unresectable colorectal liver metastases may become resectable after chemotherapy. NGS confirmed prior identified KRAS mutations in 4/29 patients (14.8%) and revealed further somatic RAS alterations in 5 cases.
BACKGROUND/AIMS: Initially unresectable colorectal liver metastases may become resectable after chemotherapy. NGS confirmed prior identified KRAS mutations in 4/29 patients (14.8%) and revealed further somatic RAS alterations in 5 cases.
What the study was
- Study design
- Retrospective study
- Sample size
- 30
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- PloS one
Why it surfaced
Low-signal Precision oncology and genomic medicine entry (Retrospective study design); retained for topic coverage completeness.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.